[Tool for the assessment of drugs for the treatment of inborn errors of metabolism. Anderson- Fabry disease]
Abdel-Kader Martin L, Castillo Munoz MA
Record ID 32010001473
English, Spanish
Authors' recommendations:
The results provide the list of clinically relevant endpoints which will be used for monitoring the treatment and assess efficacy individually.Most of the studies measure the efficacy of the specific treatment through surrogate endpoints and not through clinically relevant endpoints.The results of this study supply the health professionals a help to start and assess clinical studies that assesses the efficacy of the specific treatment in patients with AFD.
Details
Project Status:
Completed
Year Published:
2010
URL for published report:
https://www.aetsa.org/download/publicaciones/antiguas/AETSA_2007-05-1_Anderson_Fabry.pdf
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Spain
MeSH Terms
- Metabolism, Inborn Errors
- Fabry Disease
Contact
Organisation Name:
Andalusian Health Technology Assessment Area
Contact Address:
Area de Evaluacion de Tecnologias Sanitarias Sanitarias de Andalucia (AETSA) Avda. Innovación, s/n Edificio Arena 1. Sevilla (Spain) Tel. +34 955 006 309
Contact Name:
aetsa.csalud@juntadeandalucia.es
Contact Email:
aetsa.csalud@juntadeandalucia.es
Copyright:
Andalusian Agency for Health Technology Assessment (AETSA)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.